Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference

On November 12, 2020 Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, reported that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference. See below for more details (Press release, Enlivex Therapeutics, NOV 12, 2020, View Source [SID1234570730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: H.C. Wainwright 6th Annual Israel Conference

Format: Fireside chat (virtual)

Date & Time: Thursday November 12, 10:00 EST.

Webcast Link: View Source

During the fireside chat, company management will provide an update on the clinical and preclinical development of AllocetraTM for the following indications:

Sepsis

·Phase IIb trial in sepsis patients remains on track for initiation in Q4 2020.
·This Phase IIb trial expects to enroll up to 160 patients.
·Interim clinical results are expected in Q3 2021.
COVID-19

·Phase II trial ongoing, interim clinical results expected by year-end 2020.
·Approved vaccines are not expected to eliminate the need for effective COVID-19 treatments.
oAssuming approved vaccines will have an average efficacy of 85%, expected cases of severe and critical COVID-19 are likely to be at 15% of the rate of current severe/critical cases.
oSome of the population may choose to remain unvaccinated.
·Positive Phase II data, if obtained, could potentially open regulatory pathways to initiate clinical trials in other indications associated with organ dysfunction and failure.
Solid Cancers

·Additional preclinical characterization of the mechanism of action of AllocetraTM in solid cancers that have no effective therapies remains ongoing.
·Enlivex is working to establish preclinical and clinical collaborations with leading cancer medical centers in the U.S.